Skip to Main Content

It’s remarkable to watch Omeros CEO Greg Demopulos and his executive team dissolve into a pool of obfuscation and incompetence when the truth finally arrives.

The company said Monday that the Food and Drug Administration rejected its drug called narsoplimab meant to treat patients with a rare but often-deadly complication of bone marrow transplants. The denial finally revealed what many Omeros critics — myself, included — have known for years. The clinical development of narsoplimab was built on shaky, often nonsensical clinical data and a mountain of misleading statements about FDA agreements.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment